Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News | August 31, 2011

August 31, 2011 — Results of a recent randomized controlled study show the drug-eluting stent Xience V performs well...

News | August 17, 2011

August 17, 2011 — OrbusNeich announced its Genous stent showed no significant difference in target vessel failure (...

News | August 09, 2011

August 9, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the First Circuit has affirmed the...

News | July 29, 2011

July 29, 2011 — Boston Scientific Corporation's board of directors has approved a five-year, $150 million investment...

News | July 27, 2011

July 27, 2011 – Micell Technologies Inc. announced that it has completed patient...

News | July 26, 2011

July 26, 2011 – The Resolute drug-eluting stent (DES) from Medtronic Inc. showed superiority to Boston Scientific...

Technology | April 27, 2011

April 26, 2011 – The U.S. Food and Drug Administration (FDA) announced this week it cleared Boston Scientific’s Ion...

The Cook Zilver PTX self-expanding stent may become the first drug-eluting stent available in the United States if it is cleared by the FDA later this year.

Feature | July 15, 2011 | Dave Fornell

The goal of treating peripheral artery disease (PAD) in the superficial femoral artery (SFA) is limb salvage and...

Medtronic has introduced a new stent platform called Integrity, which is made of a cobalt alloy and utilizes sinusoid technology to make each stent from one continuous wire. It is extremely flexible, even in tortuous vessels.

Feature | July 15, 2011 | By Karene Dumoulin, Principal Analyst, Millennium Research Group

Navigating through the world of coronary stents is about to become more complex.  A plethora of new products are on...

News | June 30, 2011

June 30, 2011 — Micell Technologies Inc. announced that it has completed its review of the scheduled four-month...

Technology | June 16, 2011

June 16, 2011 — Johnson & Johnson subsidiary Cordis International announced Wednesday that it will cease...

News | June 03, 2011

June 3, 2011 – New long-term data from the DIVERGE study, presented at EuroPCR 2011, showed that the use of the...

Technology | May 25, 2011

May 25, 2011 – Boston Scientific Corp. today announced it received approval from the U.S. Food and Drug...

Technology | May 25, 2011

May 25, 2011 – The U.S. Food and Drug Administration (FDA) cleared the Xience nano everolimus-eluting coronary stent...

News | May 24, 2011

May 24, 2011 — Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical...

Overlay Init